VENETOCLAX AND RITUXIMAB (VENR) FOR THE FRONT-LINE TREATMENT OF YOUNG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND AN UNFAVORABLE BIOLOGIC PROFILE. PRELIMINARY RESULTS OF THE GIMEMA VERITAS STUDYF. R. Mauro, G. Reda,V. Arena, A. Visentin,M. Coscia,P. Sportoletti,L. Laurenti, G. Gaidano, R. Marasca,L. Orsucci, R. Murru,C. Stelitano,F. Ilariucci, D. Mannina, M. Massaia,G. M. Rigolin, L. Scarfo,M. Marchetti,L. Levato,M. Tani,A. Arcari,G. Musuraca, M. Deodato, P. Galieni, V. Belsito Patrizi,D. Gottardi,A. M. Liberati,D. Pietrasanta,S. Molica,R. Cassin,C. Vitale, C. Ielo,M. S. De Propris,I. Della Starza,S. Raponi,M. Nanni,I. Del Giudice, F. Paoloni,P. Fazi, F. Albano,A. Neri, A. Piciocchi, L. Trentin, A. Cuneo,A. Guarini,R. FoaHAEMATOLOGICA（2021）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
